MX2007007026A - Derivados de tieno-piridina como intensificadores alostericos de gaba-b. - Google Patents

Derivados de tieno-piridina como intensificadores alostericos de gaba-b.

Info

Publication number
MX2007007026A
MX2007007026A MX2007007026A MX2007007026A MX2007007026A MX 2007007026 A MX2007007026 A MX 2007007026A MX 2007007026 A MX2007007026 A MX 2007007026A MX 2007007026 A MX2007007026 A MX 2007007026A MX 2007007026 A MX2007007026 A MX 2007007026A
Authority
MX
Mexico
Prior art keywords
thieno
gaba
pyridine derivatives
allosteric enhancers
allosteric
Prior art date
Application number
MX2007007026A
Other languages
English (en)
Inventor
Raffaello Masciadri
Andrew William Thomas
Roger David Norcross
Hasane Ratni
Parichehr Malherbe
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of MX2007007026A publication Critical patent/MX2007007026A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system having sulfur as a ring hetero atom, e.g. ticlopidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D495/14—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Neurology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Pain & Pain Management (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Epidemiology (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)

Abstract

La presente invencion se refiere a compuestos de la formula (I), en donde R1 a R5 son como se definen en la especificacion cuyos compuestos son activos sobre el receptor GABAB y se pueden utilizar para la fabricacion de medicamentos utiles para tratar trastornos del SNC.
MX2007007026A 2004-12-17 2005-12-09 Derivados de tieno-piridina como intensificadores alostericos de gaba-b. MX2007007026A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP04106665 2004-12-17
PCT/EP2005/013194 WO2006063732A1 (en) 2004-12-17 2005-12-09 Thieno-pyridine derivatives as gaba-b allosteric enhancers

Publications (1)

Publication Number Publication Date
MX2007007026A true MX2007007026A (es) 2007-07-04

Family

ID=35702999

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2007007026A MX2007007026A (es) 2004-12-17 2005-12-09 Derivados de tieno-piridina como intensificadores alostericos de gaba-b.

Country Status (17)

Country Link
US (1) US7390903B2 (es)
EP (1) EP1828199B1 (es)
JP (1) JP2008524134A (es)
KR (1) KR100912145B1 (es)
CN (1) CN101120003B (es)
AR (1) AR051995A1 (es)
AT (1) ATE430751T1 (es)
AU (1) AU2005315937A1 (es)
BR (1) BRPI0519521A2 (es)
CA (1) CA2591211A1 (es)
DE (1) DE602005014383D1 (es)
ES (1) ES2324231T3 (es)
MX (1) MX2007007026A (es)
PL (1) PL1828199T3 (es)
RU (1) RU2388761C2 (es)
TW (1) TW200633708A (es)
WO (1) WO2006063732A1 (es)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0622472D0 (en) * 2006-11-10 2006-12-20 Addex Pharmaceuticals Sa Novel heterocyclic derivatives
US8633186B2 (en) 2007-06-08 2014-01-21 Senomyx Inc. Modulation of chemosensory receptors and ligands associated therewith
AU2013202912B2 (en) * 2007-06-08 2016-10-27 Firmenich Incorporated Modulation of chemosensory receptors and ligands associated therewith
US9603848B2 (en) * 2007-06-08 2017-03-28 Senomyx, Inc. Modulation of chemosensory receptors and ligands associated therewith
US7928111B2 (en) * 2007-06-08 2011-04-19 Senomyx, Inc. Compounds including substituted thienopyrimidinone derivatives as ligands for modulating chemosensory receptors
RU2511315C2 (ru) 2008-07-31 2014-04-10 Синомикс, Инк. Композиции, содержащие усилители сладкого вкуса, и способы их получения
KR101523126B1 (ko) 2008-07-31 2015-05-26 세노믹스, 인코포레이티드 단맛 향상제의 제조 방법 및 중간체
GB0908394D0 (en) 2009-05-15 2009-06-24 Univ Leuven Kath Novel viral replication inhibitors
GB0913636D0 (en) 2009-08-05 2009-09-16 Univ Leuven Kath Novel viral replication inhibitors
CA2792068A1 (en) 2010-04-02 2011-10-06 Senomyx, Inc. Sweet flavor modifier
BR112013003332B1 (pt) 2010-08-12 2018-11-13 Senomyx, Inc. método para melhorar a estabilidade de intensificador de doce e composição contendo intensificador de doce estabilizado
WO2012065963A2 (en) 2010-11-15 2012-05-24 Katholieke Universiteit Leuven Novel antiviral compounds
MX343274B (es) * 2010-11-15 2016-10-31 Viiv Healthcare Uk Ltd Inhibidores de la replicacion del vih.
CA2841012C (en) 2011-08-12 2019-07-30 Senomyx, Inc. Sweet flavor modifier
ES2606637T3 (es) * 2012-02-09 2017-03-24 Merck Patent Gmbh Derivados de furo [3,2- b]piridina como inhibidores de TBK1 e IKK
CN104603132B (zh) 2012-08-06 2020-02-21 弗门尼舍公司 甜味调节剂
JO3155B1 (ar) 2013-02-19 2017-09-20 Senomyx Inc معدِّل نكهة حلوة
US9908893B2 (en) 2013-06-11 2018-03-06 Latvian Institute Of Organic Synthesis Thieno [2,3-b] pyridines as multidrug resistance modulators
PL3030568T3 (pl) 2013-08-08 2019-03-29 Galapagos Nv Tieno[2,3-c]pirany jako modulatory cftr
TWI648281B (zh) * 2013-10-17 2019-01-21 日商安斯泰來製藥股份有限公司 含硫二環式化合物
TW201623257A (zh) 2014-05-09 2016-07-01 奧利安公司 藥理活性之喹唑啉二酮衍生物
AU2015343463A1 (en) 2014-11-07 2017-06-15 Senomyx, Inc. Substituted 4-amino-5-(cyclohexyloxy)quinoline-3-carboxylic acids as sweet flavor modifiers
MA46899A (fr) * 2016-11-07 2021-04-14 Univ Vanderbilt Modulateurs allostériques positifs du récepteur muscarinique de l'acétylcholine m4
MX2021001193A (es) 2018-08-07 2021-04-28 Firmenich Incorporated 2,2-dioxidos de 4-amino-1h-benzo[c][1,2,6]tiadiazina 5-sustituidos y formulaciones y usos de los mismos.
CN109081846A (zh) * 2018-10-08 2018-12-25 浙江工业大学上虞研究院有限公司 4-氨基噻吩[2,3-b]吡啶类化合物的制备方法

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1003419A (en) * 1971-11-23 1977-01-11 Theodor Denzel Process for the production of pyrazolo (3,4-b) pyridines
GB8801491D0 (en) * 1988-01-22 1988-02-24 Beecham Group Plc Novel compounds
GB8804448D0 (en) * 1988-02-25 1988-03-23 Smithkline Beckman Intercredit Compounds
GB8921304D0 (en) * 1989-09-20 1989-11-08 Wyeth John & Brother Ltd New method of treatment and heterocyclic compounds used therein
US6313146B1 (en) 1991-08-23 2001-11-06 Nps Pharmaceuticals, Inc. Calcium receptor-active molecules
EP0612323A1 (en) * 1991-11-07 1994-08-31 Smithkline Beecham Plc Cns active tetrahydrobenzothienopyridines
AU699354B2 (en) * 1994-11-08 1998-12-03 Takeda Chemical Industries Ltd. Thienopyridine or thienopyrimidine derivatives useful as anti-inflammatory agents or in the treatment of osteoporosis
FR2800072B1 (fr) 1999-10-22 2002-01-11 Centre Nat Rech Scient 1-(2-butyrolactones et 2-thiobutyrolactones)-isoquinolines n-substituees utiles comme stimulant de l'activite de l'acide gamma-aminobutyrique et dans le traitement des troubles nerveux et leur procede de preparation
WO2001056990A2 (en) 2000-02-03 2001-08-09 Eli Lilly And Company Pyridine derivates as potentiators of glutamate receptors
JP2004506038A (ja) * 2000-08-16 2004-02-26 ニューロゲン　コーポレイション ２，４−置換ピリジン誘導体
GB0209481D0 (en) 2002-04-24 2002-06-05 Novartis Ag Organic compounds

Also Published As

Publication number Publication date
WO2006063732A1 (en) 2006-06-22
JP2008524134A (ja) 2008-07-10
ES2324231T3 (es) 2009-08-03
KR100912145B1 (ko) 2009-08-14
US20060135552A1 (en) 2006-06-22
PL1828199T3 (pl) 2009-10-30
TW200633708A (en) 2006-10-01
DE602005014383D1 (en) 2009-06-18
AR051995A1 (es) 2007-02-21
CN101120003B (zh) 2010-06-16
BRPI0519521A2 (pt) 2009-02-10
RU2388761C2 (ru) 2010-05-10
KR20070091016A (ko) 2007-09-06
RU2007121908A (ru) 2009-01-27
EP1828199B1 (en) 2009-05-06
AU2005315937A1 (en) 2006-06-22
EP1828199A1 (en) 2007-09-05
US7390903B2 (en) 2008-06-24
CN101120003A (zh) 2008-02-06
ATE430751T1 (de) 2009-05-15
CA2591211A1 (en) 2006-06-22

Similar Documents

Publication Publication Date Title
MX2007007026A (es) Derivados de tieno-piridina como intensificadores alostericos de gaba-b.
ATE478876T1 (de) Thienopyridine als allosterische verstärker des m4-muscarinrezeptors
TW200740814A (en) Compounds
UY28774A1 (es) Derivados de heteroarilaminopirazol utiles para el tratamiento de la diabetes.
MXPA06014721A (es) Derivados de alquinilo como moduladores de los receptores de glutamato metabotropico.
UA92914C2 (ru) Гетероциклические соединения как положительные аллостерические модуляторы метаботропных глутаматных рецепторов
EA200870471A1 (ru) Замещенные пирролидиноны в качестве ингибиторов 11-бета-гидроксистероиддегидрогеназы 1 типа
JO2853B1 (en) Sulfonamides as TRPM8 organizations
MX2009003316A (es) Derivados de pirazina-2-carboxamida como moduladores receptores de cb2.
GB0625648D0 (en) Compounds
TW200700391A (en) Pyridine-2-carboxamide derivatives as mglur5 antagonists
WO2007053765A3 (en) Substituted cycloalkylpyrrolones as allosteric modulators of glucokinase
MX2010005649A (es) Compuestos novedosos como ligandos del receptor canabinoide y sus usos.
GB0510140D0 (en) Novel compounds B2
JO2682B1 (en) Derivatives of alkynil-8.1-naphthayridone, preparations thereof and therapeutic use thereof
MX2009000480A (es) Bencilaminas, un proceso para su produccion y su uso como agentes antiinflamatorios.
TW200716564A (en) Tetrahydronaphthalene derivatives, process for their production and their use as anti-inflammatory agents
NO20084301L (no) Tetrahydronaftalenderivater, fremgangsmate for deres fremstilling og anvendelse derav som anti-inflammatoriske midler
SI1831239T1 (sl) Postopek za pripravo gamma laktona hidroksi beta beta beta beta bismetilen alfa pregn en on karboksilne kisline in ključniintermediati za ta postopek
MX2007005112A (es) Quinolinas como intensificadores alostericos de receptores de acido gamma-aminobutirico-b.
WO2008104473A3 (en) Pyrazolopyriidine derivatives and their use as kinase inhibitors
TW200621703A (en) Alkylidene-tetrahydronaphthalene derivatives, process for their production and their use as anti-inflammatory agents
WO2006128802A3 (en) 3-methanesulfonylquinolines as gaba-b enhancers
TW200613317A (en) Steroid prodrugs with androgenic action
SE0403085D0 (sv) Novel componds

Legal Events

Date Code Title Description
FG Grant or registration